Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62,603 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y, Yuan Y, Feng J, Chen Z, Shi J, Sun T, Wu G, Shu Y, Guo Q, Zhang Y, Song Y, Zhang S, Chen Y, Li W, Niu H, Hu W, Wang L, Huang J, Zhang Y, Cheng Y, Wu Z, Peng B, Sun J, Mancao C, Wang Y, Sun L. Shi Y, et al. Among authors: wang l, wang z, wang j, wang y, wang m, wang c, wang a. Cancer Commun (Lond). 2022 Dec;42(12):1314-1330. doi: 10.1002/cac2.12385. Epub 2022 Nov 6. Cancer Commun (Lond). 2022. PMID: 36336841 Free PMC article. Clinical Trial.
[The relationship between EGFR mutations and response and prognosis of tyrosine kinase inhibitors in advanced Non-small-cell Lung Cancer.].
Zhang X, Xu L, Wang H, Zhu Y, Liu Z, Yue W, Tang J, Wu W, Liu Z, Wu Y, Zhang C, Shi Y, Wang M, Shi H, Li M, Meng Q, Guo L, Wang J, Li X. Zhang X, et al. Among authors: wang h, wang j, wang m. Zhongguo Fei Ai Za Zhi. 2008 Apr 20;11(2):206-13. doi: 10.3779/j.issn.1009-3419.2008.02.016. Zhongguo Fei Ai Za Zhi. 2008. PMID: 20731903 Free article. Chinese.
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.
Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; INFORM investigators. Zhang L, et al. Among authors: wang j, wang m. Lancet Oncol. 2012 May;13(5):466-75. doi: 10.1016/S1470-2045(12)70117-1. Epub 2012 Apr 17. Lancet Oncol. 2012. PMID: 22512843 Clinical Trial.
[Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
Hu X, Jiao S, Zhang S, Wang Z, Wang M, Huang C, Zheng R, Li K, Wang J, Wang Y, Ouyang X, Lv W, Cheng G, Hu C, Luo R, Sun Y. Hu X, et al. Among authors: wang z, wang j, wang y, wang m. Zhongguo Fei Ai Za Zhi. 2012 Oct;15(10):569-75. doi: 10.3779/j.issn.1009-3419.2012.10.02. Zhongguo Fei Ai Za Zhi. 2012. PMID: 23075680 Free PMC article. Clinical Trial. Chinese.
[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
Huang Y, Liu Y, Zhou J, Xu N, Li B, Wu G, Fang J, Li K, Liu X, Liu W, Lu Y, Wang M, Liu W, Liang H, Zhang Y, Huang C, Wang S, Wang Y, Yu S, Chang J, Wang Z, Hu Z, Zhang L. Huang Y, et al. Among authors: wang z, wang y, wang m, wang s. Zhongguo Fei Ai Za Zhi. 2012 Oct;15(10):576-82. doi: 10.3779/j.issn.1009-3419.2012.10.03. Zhongguo Fei Ai Za Zhi. 2012. PMID: 23075681 Free PMC article. Clinical Trial. Chinese.
[Progress in immunotherapy for non-small cell lung cancer].
Xu Y, Wang M. Xu Y, et al. Among authors: wang m. Zhongguo Fei Ai Za Zhi. 2014 Jan;17(1):34-41. doi: 10.3779/j.issn.1009-3419.2014.01.06. Zhongguo Fei Ai Za Zhi. 2014. PMID: 24398312 Free PMC article. Review. Chinese.
Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.
Wu YL, Lu S, Cheng Y, Zhou C, Wang M, Qin S, Lu Y, Zhang Y, Zhu Y, Song X, Wang X, Barraclough H, Zhang X, Chi H, Orlando M. Wu YL, et al. Among authors: wang x, wang m. Lung Cancer. 2014 Sep;85(3):401-7. doi: 10.1016/j.lungcan.2014.07.007. Epub 2014 Jul 17. Lung Cancer. 2014. PMID: 25082564 Clinical Trial.
A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers.
Liu KJ, Guan ZZ, Liang Y, Yang XQ, Peng J, Huang H, Shao QX, Wang MZ, Zhu YZ, Wu CP, Wang SB, Xiong JP, Bai YX, Yu SY, Zhang Y, Hu XH, Feng JF, Wu SX, Jiao SC, Zhou CC, Wang J, Wu HY. Liu KJ, et al. Arch Med Sci. 2014 Aug 29;10(4):717-24. doi: 10.5114/aoms.2014.44862. Arch Med Sci. 2014. PMID: 25276156 Free PMC article.
Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804).
Zhao H, Fan Y, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Wang M, Zhang L; INFORM investigators. Zhao H, et al. Among authors: wang j, wang m. J Thorac Oncol. 2015 Apr;10(4):655-64. doi: 10.1097/JTO.0000000000000445. J Thorac Oncol. 2015. PMID: 25546556 Free article. Clinical Trial.
62,603 results
You have reached the last available page of results. Please see the User Guide for more information.